Anatomy of a long-delayed biotech buyout: With its stock price beaten down, abandoned by potential bidders, Tesaro wound up in GSK’s eager arms

When the board at Tesaro $TSRO first cheered on a move to sell the company on February 23rd, 2017, spurred by a nod from an interested pharma player as their PARP drug Zejula closed in a near-certain FDA approval, the sizzling-hot stock was selling at more than $186 a share.